Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia.

Literature DB >> 25404016

Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia.

Hiroshi Mabuchi¹, Atsushi Nohara¹.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2014 PMID： 25404016 DOI： 10.1038/nrendo.2014.205

Source DB: PubMed Journal: Nat Rev Endocrinol ISSN： 1759-5029 Impact factor: 43.330

× No keyword cloud information.

10 in total

1. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors: Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal: N Engl J Med Date: 2006-03-23 Impact factor: 91.245

2. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

Authors: Terry A Jacobson; Matthew K Ito; Kevin C Maki; Carl E Orringer; Harold E Bays; Peter H Jones; James M McKenney; Scott M Grundy; Edward A Gill; Robert A Wild; Don P Wilson; W Virgil Brown
Journal: J Clin Lipidol Date: 2014-07-15 Impact factor: 4.766

3. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

Authors: Evan A Stein; Scott Mellis; George D Yancopoulos; Neil Stahl; Douglas Logan; William B Smith; Eleanor Lisbon; Maria Gutierrez; Cheryle Webb; Richard Wu; Yunling Du; Therese Kranz; Evelyn Gasparino; Gary D Swergold
Journal: N Engl J Med Date: 2012-03-22 Impact factor: 91.245

4. Lowering plasma cholesterol by raising LDL receptors.

Authors: M S Brown; J L Goldstein
Journal: N Engl J Med Date: 1981-08-27 Impact factor: 91.245

5. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.

Authors: H Mabuchi; T Haba; R Tatami; S Miyamoto; Y Sakai; T Wakasugi; A Watanabe; J Koizumi; R Takeda
Journal: N Engl J Med Date: 1981-08-27 Impact factor: 91.245

6. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors: Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal: Nat Genet Date: 2003-06 Impact factor: 38.330

7. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.

Authors: Hiroshi Mabuchi; Atsushi Nohara; Tohru Noguchi; Junji Kobayashi; Masa-aki Kawashiri; Takeshi Inoue; Mika Mori; Hayato Tada; Chiaki Nakanishi; Kunimasa Yagi; Masakazu Yamagishi; Kousei Ueda; Tadayoshi Takegoshi; Susumu Miyamoto; Akihiro Inazu; Junji Koizumi
Journal: Atherosclerosis Date: 2014-06-26 Impact factor: 5.162

8. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.

Authors: Frederick J Raal; Narimon Honarpour; Dirk J Blom; G Kees Hovingh; Feng Xu; Rob Scott; Scott M Wasserman; Evan A Stein
Journal: Lancet Date: 2014-10-01 Impact factor: 79.321

9. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.

Authors: Frederick J Raal; Evan A Stein; Robert Dufour; Traci Turner; Fernando Civeira; Lesley Burgess; Gisle Langslet; Russell Scott; Anders G Olsson; David Sullivan; G Kees Hovingh; Bertrand Cariou; Ioanna Gouni-Berthold; Ransi Somaratne; Ian Bridges; Rob Scott; Scott M Wasserman; Daniel Gaudet
Journal: Lancet Date: 2014-10-01 Impact factor: 79.321

Review 10. Mechanisms of disease: genetic causes of familial hypercholesterolemia.

Authors: Anne K Soutar; Rossi P Naoumova
Journal: Nat Clin Pract Cardiovasc Med Date: 2007-04

10 in total

5 in total

Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia.

1. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

2. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

3. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

4. Lowering plasma cholesterol by raising LDL receptors.

5. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.

6. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

7. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.

8. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.

9. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.

Review 10. Mechanisms of disease: genetic causes of familial hypercholesterolemia.

Review 1. Hypertension pharmacogenomics: in search of personalized treatment approaches.

Review 2. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

Review 3. Plaque imaging to refine indications for emerging lipid-lowering drugs.

4. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

Review 5. Lipid Lowering Therapy and Circulating PCSK9 Concentration.